Who’s Hired? ANI Pharma Strengthens Leadership With Three New Executives
Coherus And Xbrane Appoint New CFOs
Executive Summary
ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.
You may also be interested in...
ANI Refiles Cortrophin After Talks With FDA
US-based ANI Pharmaceuticals has made manufacturing and API changes as part of its refiled package for Cortrophin Gel (corticotropin) for injection, which it hopes will be a “transformational opportunity.”
ANI Transforms With Novitium And Sandoz Deals
US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches.
ANI Has Four-Pillar Growth Strategy Following Novitium Deal
With a four-pillar growth strategy, ANI Pharma plans over 25 product launches in 2021 and 2022. With the recent acquisition of Novitium the company is also advancing three 505(b)(2) candidates in oncology and hypertension, after seeing a slight growth in overall revenues and generics sales in 2020.